Lactoferrin is one of the few supplements with strong RCT evidence specifically in pregnant women. It treats anemia, reduces preterm birth risk, and modulates GBS colonization — with a safety profile inherited from its 30-year history in infant formula.
Pregnancy is a uniquely challenging context for supplementation. Most dietary supplements lack pregnancy-specific safety data, and many are explicitly avoided. Lactoferrin is a notable exception — it has been studied in pregnant women in multiple randomized trials, has GRAS status, and has been added to infant formula globally for decades. The 2026 evidence supports several specific applications.
Iron deficiency anemia affects 30–50% of pregnant women globally. Standard ferrous sulfate (300–325 mg, providing ~100 mg elemental iron) works but causes nausea, constipation, and metallic taste in up to 50% of women — at exactly the time when nausea tolerance is already at its lowest.
The pivotal Italian trials (Paesano, Pietropaoli, Berlutti, Caputo, Polimeni, Valenti — multiple publications 2009–2014) randomized hundreds of pregnant women with confirmed iron deficiency anemia to either ferrous sulfate or bovine lactoferrin 200 mg twice daily. Results consistently showed:
The Italian Society of Gynecology and Obstetrics has formally added lactoferrin to anemia guidelines as an alternative first-line option. See our iron deficiency anemia article for the broader anemia evidence.
A 2017 Cochrane analysis and subsequent trials have documented that lactoferrin supplementation reduces inflammatory markers (hsCRP, IL-6) implicated in preterm labor. Two RCTs in women at elevated risk (history of preterm birth, bacterial vaginosis, or short cervix) showed lactoferrin reduced preterm delivery rates by approximately 40% compared to placebo, when started in the second trimester.
The mechanism likely involves three pathways:
1. Vaginal microbiome stabilization — reducing the Gardnerella and other anaerobic overgrowth associated with bacterial vaginosis
2. Reduced systemic inflammation — lower IL-6 reduces the inflammatory cascade that triggers preterm contractions
3. Reduced subclinical chorioamnionitis — fewer ascending bacterial infections of fetal membranes
This is not yet established as standard care, but is being incorporated into protocols at high-risk obstetric centers.
GBS colonization affects 10–30% of pregnant women and requires intrapartum antibiotic prophylaxis to prevent neonatal sepsis. Small studies suggest oral and topical (vaginal) lactoferrin can reduce GBS colonization rates, potentially reducing the need for IV antibiotics during labor. The evidence is promising but not yet definitive.
Lactoferrin's safety in pregnancy is supported by:
The single contraindication is severe cow's milk protein allergy.
Lactoferrin does not substitute for:
Lactoferrin during breastfeeding is also well-studied and safe:
For mastitis specifically, several small studies show lactoferrin 200 mg twice daily plus standard care reduces recurrence and shortens episode duration.
Quality is more important in pregnancy than in any other context. Look for:
Is bovine lactoferrin safe during the first trimester? Yes, with the standard caveat that pregnancy supplementation should always be discussed with your obstetrician. The available data show no first-trimester risk.
Can I take lactoferrin if I have gestational diabetes? Yes. Lactoferrin does not affect blood glucose and may modestly improve insulin sensitivity.
Is it safe with progesterone supplementation? Yes, no interaction.
Will my baby benefit if I take lactoferrin? Indirectly — if you have fewer inflammatory complications, less anemia, and better gut health, this benefits the baby. There is no direct fetal supplementation effect because lactoferrin is digested before crossing the placenta.
Should I continue postpartum? Yes, particularly for iron stores recovery. Continue for 3–6 months postpartum or until iron studies normalize.